Alpha Cognition (NASDAQ:ACOG) Stock Rating Upgraded by Wall Street Zen

Alpha Cognition (NASDAQ:ACOG) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Alpha Cognition in a research report on Friday, May 22nd. Craig Hallum reissued a “buy” rating and issued a $17.00 price target on shares of Alpha Cognition in a research report on Friday. Raymond James Financial started coverage on shares of Alpha Cognition in a research note on Friday, July 10th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Maxim Group started coverage on shares of Alpha Cognition in a report on Friday, May 29th. They issued a “buy” rating and a $12.00 price objective for the company. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $16.75.

Alpha Cognition Price Performance

Shares of NASDAQ ACOG opened at $8.84 on Friday. The stock has a market capitalization of $192.45 million, a PE ratio of -8.04 and a beta of 2.30. Alpha Cognition has a one year low of $4.50 and a one year high of $10.00. The business’s fifty day moving average price is $7.74 and its 200-day moving average price is $6.52.

Alpha Cognition (NASDAQ:ACOG) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%.The firm had revenue of $6.00 million during the quarter, compared to analysts’ expectations of $4.38 million. As a group, equities analysts expect that Alpha Cognition will post -1.37 EPS for the current fiscal year.

Institutional Trading of Alpha Cognition

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new stake in Alpha Cognition in the second quarter worth approximately $112,000. Massar Capital Management LP bought a new position in Alpha Cognition during the second quarter valued at approximately $116,000. Two Sigma Investments LP purchased a new position in shares of Alpha Cognition during the third quarter worth approximately $148,000. Connective Capital Management LLC purchased a new position in shares of Alpha Cognition during the third quarter worth approximately $312,000. Finally, ACT Capital Management LLC bought a new stake in shares of Alpha Cognition in the 4th quarter worth approximately $335,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.